Table 3 Logistic regression analysis for D2T RA among RA patients

Age

0.99 (0.98, 1.00)

0.180

0.98 (0.96, 0.99)

0.001

Sex, female

1.6 (1.03, 2.47)

0.033

1.72 (0.92, 3.20)

0.087

BMI

0.97 (0.93, 1.02)

0.247

1 (0.95, 1.04)

0.841

Current, ex- smoker

0.91 (0.61, 1.35)

0.608

1.37 (0.77, 2.43)

0.283

Disease duration

1.06 (1.04, 1.07)

< 0.001

1.06 (1.04, 1.08)

< 0.001

Patient global assessment

1.05 (0.97, 1.13)

0.21

0.89 (0.79, 1.00)

0.045

Physician global assessment

1.09 (1.01, 1.19)

0.037

1.1 (0.98, 1.23)

0.121

DAS28-ESR

1.14 (0.99, 1.30)

0.055

1.01 (0.72, 1.41)

0.973

DAS28-CRP

1.16 (1.01, 1.33)

0.031

0.79 (0.5, 1.26)

0.325

SDAI

1.02 (1.01, 1.03)

0.002

1.06 (1.01, 1.11)

0.014

CDAI

1.02 (1.00, 1.03)

0.023

0.97 (0.93, 1.01)

0.134

RAPID3

1.05 (1.03, 1.08)

< 0.001

1.06 (1.02, 1.1)

0.002

Comorbidities^a

1.28 (0.96, 1.72)

0.084

1.32 (0.93, 1.87)

0.126

RF positivity

0.72 (0.50, 1.03)

0.073

0.65 (0.43, 0.98)

0.040

Anti-CCP Ab positivity

0.92 (0.61, 1.38)

0.698

1.17 (0.73, 1.88)

0.510

Prior use of methotrexate

0.36 (0.23, 0.57)

< 0.001

0.44 (0.24, 0.81)

0.008

Prior use of sulfasalazine

0.65 (0.47, 0.9)

0.008

0.59 (0.42, 0.83)

0.003

Prior use of leflunomide

0.76 (0.57, 1.02)

0.061

0.67 (0.49, 0.92)

0.013

Concomitant methotrexate

0.57 (0.40, 0.79)

0.001

0.74 (0.47, 1.16)

0.182

Concomitant corticosteroid

0.93 (0.62, 1.40)

0.610

0.87 (0.57, 1.34)

0.528